Search Results for: drug patents

In 2013, the USPTO issued 277,861 utility patents, a new record in terms of the numbers of patent grants, and an increase of 9.8 percent over 2012.*

Country of Assignment

Of the total, 126,574 (45.6 percent) were assigned to a US owner, a small increase in the percent held by US entities over 2012.

Continue Reading →

Seven out of eight persons want the NIH to use its rights in federally funded patents to prevent U.S. consumers from paying more than other high income countries, according to a survey of 170 randomly selected U.S. residents. The survey was conducted August 26 to August 28, 2013, and involved two questions regarding NIH funded drug development.

Question 1.

Continue Reading →

In any given year, the U.S. Food and Drug Administration (FDA) grants marketing approval to new drugs. The most important category* are those classified as “new molecular entities” or NMEs. Chen Xingzhi has collected data on the 2010 NMEs included in the FDA Orange Book here: http://goo.gl/W78Tbk. Some of the data are summarized below:

• Among products listed in the FDA Orange Book in 2010, 15 were classified as NMEs.
• Among all of the NMEs, 43 patents were listed in the FDA Orange Book, covering 12 of the 15 products.

Continue Reading →

As others have reported, the India Intellectual Property Appeals Board (IPAB) has upheld the compulsory license on the Bayer patents on the cancer drug sorafenib, sold under the trademark of Nexavar by Bayer.

Continue Reading →

On 17 October 2012, the State Intellectual Property Office of China submitted the following comments to the Electronic Forum of WIPO’s Standing Committee on the Law of Patents (SCP) in relation to the future work of the Committee. The written submission focused on: 1) Exceptions and Limitations to Patent Rights, 2. Quality of Patents and 3. Patents and Health. These points were encapsulated in China’s general intervention today.

[English translation by WIPO]
Continue Reading →

These are KEI’s February 17, 2013 comments on the the Bayer appeal of the compulsory license on Nexavar patents.

Comments on the the Bayer appeal of the compulsory license on Nexavar patents.

February 17, 2013

The dispute is Bayer Corporation v Natco Pharma Limited, and is being heardbefore the Intellectual Property Appellate Board At Chennai (O.R.A. no. 35/PT/2012).

Continue Reading →

On October 25, 2012, the American Medical Students Association (AMSA), Knowledge Ecology International (KEI), U.S. Continue Reading →

Continue Reading →